Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3 registrational trials with OCS-01, which aims to be the first eye drop therapy for DME ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announces that the latest findings of the DME AWARE Delphi study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. DME affects mainly a working-age population and is typically diagnosed at an average age of 52 years.1, 2 One year following diagnosis, 60% of patients are not treated2a while we know that delaying treatment is not beneficial for patients as it represents a missed opportunity to fully regain vision.